WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new preclinical data on the Company’s novel IGN ADCs, IMGN632 and IMGN779, will be presented at the upcoming American Society of Hematology (ASH) annual meeting, which is being held December 3-6, 2016 in San Diego, CA.
IMGN632, a CD123-targeting ADC and IMGN779, a CD33-targeting ADC, both use ImmunoGen’s new family of indolino-benzodiazepine cancer-killing agents called IGNs. ImmunoGen designed IGN payloads to alkylate DNA without crosslinking it. Data being presented at ASH will demonstrate that DNA-alkylating IGNs are ultra-potent, yet provide increased tolerability compared with DNA crosslinking versions.
“Accelerating our earlier-stage portfolio with an emphasis on our IGN ADCs is one of ImmunoGen’s strategic priorities, and we believe the IMGN632 and IMGN779 preclinical data being presented at ASH further demonstrate why we are excited about the potential of these programs,” said Richard Gregory, Ph.D., executive vice president and chief scientific officer of ImmunoGen.
In an oral presentation, the Company will report preclinical data demonstrating the activity of IMGN632 in multiple acute myeloid leukemia (AML) models and patient samples at concentrations far below levels that affect normal bone marrow cells, suggesting the potential for efficacy in AML patients in the absence of or with limited myelosuppression. In a separate poster presentation, preclinical data for IMGN632 will be reported demonstrating prolonged survival in AML xenograft models. Preclinical data from a combination study of IMGN779 with a PARP inhibitor, demonstrating enhanced activity in several AML models including patient derived tumor cells and a disseminated AML xenograft model, will also be presented in an investigator poster presentation.
A Phase 1 trial of IMGN779 as monotherapy in AML is ongoing with the first clinical data expected to be reported in 2017. ImmunoGen intends to submit an IND application and initiate clinical testing of IMGN632 in 2017.
Oral Presentation
Title: “A CD123-Targeting Antibody-Drug
Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia
(AML) Cells While Sparing Normal Bone Marrow Cells”
- Oral presentation, session #616: Monday, December 5, presentation time 11:45am PT. Abstract #768.
Poster Presentations
Title: “IMGN632: A CD123-Targeting
Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is
Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML)
Xenograft Models”
- Poster session #616: Sunday, December 4, 6:00-8:00pm PT. Abstract #2832.
Title: “Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models”
- Poster session #616: Saturday, December 3, 5:30-7:30pm PT. Abstract #1645.
Data will also be presented on agents which use ImmunoGen’s maytansinoid ADC technology, including IMGN529 and Biotest’s indatuximab ravtansine (BT062).
Additional information, including abstracts, can be found at www.hematology.org.
About ImmunoGen
ImmunoGen is a clinical-stage biotechnology
company that develops targeted cancer therapeutics using its proprietary
ADC technology. ImmunoGen’s lead product candidate, mirvetuximab
soravtansine, is being advanced to a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in
combination regimens for earlier-stage disease. ImmunoGen’s ADC
technology is used in Roche's marketed product, Kadcyla®, in
three other clinical-stage ImmunoGen product candidates, and in programs
in development by partners Amgen, Bayer, Biotest, CytomX, Lilly,
Novartis, Sanofi and Takeda. More information about the Company can be
found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN632 and IMGN779, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 and other reports filed with the Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161103005287/en/
